Improving Patient Adherence and Quality of Life in Relapsed/Refractory Multiple Myeloma: Anticipating and Managing Adverse Events Associated with Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the treatment and Management of Relapsed/Refractory Multiple Myeloma: What
Managed Care Needs to Know About Emerging Therapies

This is Part 2 of the series focusing on improving patient adherence and quality of life while managing adverse events in emerging therapies associated with multiple myeloma

This activity is an archive from the webinar held May 1, 2020

This activity is valid from May 1, 2020 to May 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme

Description:
Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2020, it is estimated that MM will be responsible for 12,960 new deaths and 32,110 new cases. In recent years, more treatments have become available that have increased survival numbers significantly, though prognosis still remains rather poor, especially in relapsed/refractory (R/R) disease. Fortunately for patients with R/R MM, there are several novel options that have been recently approved or are currently undergoing late stage clinical trials that have shown great promise in their ability to improve clinical outcomes.

Upon completion of this activity, participants will be able to:

  • Compare emerging therapies in relapsed/refractory multiple myeloma, including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use

  • Identify adverse events associated with emerging therapies in relapsed/refractory multiple myeloma, and select appropriate strategies to help ensure patient treatment adherence and optimal quality of life

  • Discuss methods to communicate effectively with cancer patients and the multidisciplinary team to understand and address the needs of each patient around emerging therapies in RRMM and improve treatment adherence, quality of life, and survival outcomes

  • Review how treatment strategies can be affected by adverse events based on patient’s individualized needs

  • Analyze strategies to monitor and manage adverse events associated with emerging anti-CD38
     

Faculty: Ravi Vij, MD, MBA
Professor, Section of BMT and Leukemia
Division of Medical Oncology
Washington University School of Medicine

Disclosure:

Dr. Vij has served on an advisory board for Bristol-Myers Squibb, Karyopharm, Genentech, GSK, Sanofi, Oncopeptides, Securabio, Janssen, and Takeda. He has received grants/research support from Bristol-Myers Squibb, Sanofi and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue